CC

Clinical Cancer Research

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; immunotherapy; gene therapy; diagnostic biomarkers; innovative imaging, and clinical genetics.

Looking to publish in Clinical Cancer Research? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Existing customer login
Subject Oncology
Impact Factor 10.2
Quartile Q1
Open Access Type Closed
ISSN 1078-0432
eISSN 1557-3265
Invitation Only No
Cost Range Publication involves a base publication fee and an additional fee for each display item; authors may apply for a waiver of the fixed publication fee if no financial support exists.

Submission Instructions

Clinical Cancer Research accepts the following article types. Click on an article type to view submission instructions.

Original Research Articles

Cover Letter Cover letter is not required but authors are strongly encouraged to upload one. Any use of AI to produce new text, images, or other material for the manuscript must be described in detail in the cover letter.
Abstract An abstract is required.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript should include Title Page, a 150-word translational relevance statement on a separate page before the abstract, Abstract, Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Methods. Manuscript must include a 150-word translational relevance statement, a conflict of interest disclosure on the title page, an AI-use declaration in the acknowledgments and manuscript as applicable, a Data Availability Statement, and a Code Availability Statement when custom code was used.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors.
Figures & Tables For initial submission, figures should be on the same page as the legend either at the end of the manuscript file or embedded in the text near the figure callout, and supplementary data should be uploaded separately. Each figure must have a legend, figures and tables must be cited and numbered in the order they appear, and figure legends must include the number of technical and biological replicates.
Reformat to Clinical Cancer Research using Livewrite Premium

Review Manuscript

Cover Letter Cover letter is strongly encouraged but not required. Cover letters for review articles are not required at submission, but presubmission inquiries should include an outline or draft and a list of key references if available.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. The manuscript should include Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Materials and Methods. The title page must include the word count, total number of figures and tables, and a conflict of interest statement, and any use of generative artificial intelligence or human-assisted editing services must be declared in the acknowledgments or other appropriate manuscript section.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors.
Figures & Tables For initial submission, figures should appear on the same page as the legend either embedded near the figure callout or placed at the end of the manuscript file, and authors are strongly encouraged to upload a single manuscript file containing the text and all display items. Each figure must be numbered in text order and accompanied by a legend, and every table must have a descriptive title and enough explanatory information to be understood without reference to the text.
Reformat to Clinical Cancer Research using Livewrite Premium

Meta-Analysis

Cover Letter Cover letter is strongly encouraged but not required. Any use of AI to produce new text, images, or other material for the manuscript must be described in detail in the cover letter.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. The manuscript must include a 150-word statement of translational relevance on a page between the title page and abstract. A detailed conflict of interest disclosure statement must appear on the title page, and any use of generative artificial intelligence or human-assisted editing services must be declared in the acknowledgments section.
References References must be numbered in the order of first mention in the text, with up to 6 authors listed in full and more than 6 authors abbreviated after the first 6 with "et al.".
Figures & Tables For initial submission, figures should be embedded on the same page as the legend either near the figure callout or at the end of the manuscript file. Each table must be numbered with a descriptive title, and each figure must be numbered in text order and accompanied by a legend that defines the figure and any panel labels.
Reformat to Clinical Cancer Research using Livewrite Premium

Systematic Reviews

Cover Letter Cover letter is strongly encouraged but not required. Cover letter must describe any use of AI to produce new text, images, or other material and explain how any associated manuscript is related to the submission.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript should include Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Materials and Methods, and Systematic Reviews must follow PRISMA. A 150-word translational relevance statement must appear on a page between the title page and abstract, AI assistance in manuscript preparation must be declared in the acknowledgments, and the title page must include the word count, total number of figures and tables, and a conflict of interest disclosure statement.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors or all authors when there are 6 or fewer.
Figures & Tables For initial submission, figures should be placed on the same page as the legend either at the end of the manuscript file or embedded near the figure callout, and authors are strongly encouraged to upload a single manuscript file containing the main text and all display items. Each figure must be numbered in text order and accompanied by a legend with a short title sentence and description, including panel labels and descriptions when applicable, while every table must be numbered in Arabic numerals and include a descriptive title.
Reformat to Clinical Cancer Research using Livewrite Premium

Clinical Trials

Cover Letter Cover letter is strongly encouraged rather than required. Cover letter must describe how any associated manuscript is related to the submission, disclose any restrictions on availability of manuscript components, and detail any use of AI to produce new text, images, or other material.
Abstract Abstract is required.
Manuscript Manuscript should include the standard sections of title page, abstract, Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Materials and Methods, with a 150-word translational relevance statement placed between the title page and abstract. Manuscript must include a detailed conflict of interest disclosure on the title page, the trial registration number when applicable, an acknowledgments disclosure of any generative AI or human-assisted editing help, and a supplementary table describing cancer background and study population representativeness including patient characteristics such as sex or gender, age, race or ethnicity, and geography.
References References must be numbered in order of first mention in the text, cited in text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors or all authors when there are 6 or fewer.
Figures & Tables For initial submission, figures should be embedded in the manuscript near the figure callout or placed at the end on the same page as the legend, while supplementary data must be uploaded separately. Each figure must be numbered in text order and accompanied by a legend, and Clinical Trials must also include a supplementary table covering cancer background and the representativeness of the study population.
Reformat to Clinical Cancer Research using Livewrite Premium

Recent Publications

Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases

Benjamin L. Schlechter, Marwan G. Fakih, Apostolia M. Tsimberidou, Andrea J. Bullock, Agustin Pimentel, Sunil Sharma, Heinz-Josef Lenz, Michael S. Gordon, Ghassan K. Abou-Alfa, Thomas U. Marron, Robert W. Lentz, Wells Messersmith, Ian Chau, Bruno Bockorny, Dhan Chand, Manushak Avagyan, Wei Wu, Benny Johnson, Joseph E. Grossman, Steven J. O'Day, Anthony B. El-Khoueiry, Neil H. Segal

10.1158/1078-0432.ccr-26-1610
View Publication

Focused Ultrasound-Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling

Andrew Wu, Charuka Wickramasinghe, Yuanyuan Jiang, Xun Bao, Jing Li

10.1158/1078-0432.ccr-26-1949
View Publication

A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial

Jessica S. Ross, Winston Wong, Lauren Schoech, Alex Makhnin, Dazhi Liu, Ranieri Yllanes, Jonathan Loi, Ala'A Damrah, Amanda Johnson, Michelle S. Ginsberg, Vetri Sudar Jayaprakasam, Mark Dunphy, Ronglai Shen, Nora Katabi, Kanika Arora, Michael F. Berger, David B. Solit, Mark Y. Jeng, Charles Hsu, Alexander Drilon, Vicky Makker, Gopakumar Iyer, Rona Yaeger, Gregory J. Riely, Mark G. Kris, Bob Li, Alan Ho, Jamie E. Chaft

10.1158/1078-0432.ccr-26-1566
View Publication

A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors

Lillian L. Siu, Omid Hamid, Reva Schneider, Jordi Rodon. Ahnert, Scott A. Laurie, Frank Stephen. Hodi, Dong-Wan Kim, Myung-Ju Ahn, Gary Carlson, Hussein Assi, Hamza Khan, Patrick Hanafin, Emily Moore, Madhu Ramaswamy, Reza Mozaffari, Stefan Zajic, Arindam Dhar, Ivan Diaz Padilla, Noboru Yamamoto

10.1158/1078-0432.ccr-25-4374
View Publication

Adrenergic regulation of cancer immunity

Jingjing Zhu, Pierre-Hubert Desimpel, Constance Gérard, Benoit J. Van den Eynde

10.1158/1078-0432.ccr-23-3434
View Publication

Frequently asked questions

How long does it take to publish?

AACR member authors may receive a full refund of the journal publication fee if the time from completion of submission to the first decision after external peer review exceeds 60 days.

Reformat to Clinical Cancer Research using Livewrite Premium

Is a cover letter required?

Authors are strongly encouraged to upload a cover letter for initial submission.

Reformat to Clinical Cancer Research using Livewrite Premium

What are the publication costs?

Publication involves a base publication fee and an additional fee for each display item; authors may apply for a waiver of the fixed publication fee if no financial support exists.

Reformat to Clinical Cancer Research using Livewrite Premium

Research Topics

Cancer Genomics and Diagnostics Cancer Immunotherapy and Biomarkers Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Immunotherapy and Immune Responses Lung Cancer Treatments and Mutations Breast Cancer Treatment Studies CAR-T cell therapy research Cancer, Hypoxia, and Metabolism Cancer-related Molecular Pathways Cancer Cells and Metastasis Epigenetics and DNA Methylation PARP inhibition in cancer therapy Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology RNA modifications and cancer Prostate Cancer Treatment and Research Cancer Research and Treatments Monoclonal and Polyclonal Antibodies Research Pancreatic and Hepatic Oncology Research Ovarian cancer diagnosis and treatment PI3K/AKT/mTOR signaling in cancer Genetic factors in colorectal cancer Immune Cell Function and Interaction Lung Cancer Research Studies

Related Journals

CI
Cancer Immunology Immunotherapy Springer Science+Business Media
CC
Cancer Communications WILEY
CI
Cancer Imaging BioMed Central
Ne
Neuro-Oncology Oxford University Press
BR
Biomarker Research BioMed Central
JO
Journal of the Korean Gastric Cancer Association KOREAN GASTRIC CANCER ASSOC